AUTHORS
Renchi Yang, MD, Feng Xue, MD2, Jing Sun3, Shujie Wang4, Runhui Wu, MD, PhD5, Xingsheng Zhang, MD6, Elizabeth Clearfield, MHS7, Jamie O'Hara8, Mark W. Skinner9, Brian O'Mahony10, Alfonso Iorio, MD, PhD11
AFFILIATIONS
1 Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Institute of Hematology and Blood Diseases Hospital, Tianjin, China, National Clinical Research Center for Blood Diseases, Tianjin, China, State Key Laboratory of Experimental Hematology, Tianjin, China
2 Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Institute of Hematology and Blood Diseases Hospital, Tianjin, China
3 Nanfang Hospital, Southern Medical University, Guangzhou, China
4 Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
5 Beijing Children's Hospital, Capital Medical University, Beijing, China
6 Shandong Blood Center, Jinan, China
7 Institute for Policy Advancement, Ltd., Washington, DC, District of Columbia, United States
8 RareQV, Chester, United Kingdom
9 Institute for Policy Advancement, Ltd., Washington, DC, District of Columbia, United States, McMaster University, Hamilton, Ontario, Canada
10 Irish Haemophilia Society, Dublin, Ireland
11 McMaster University, Hamilton, Ontario, Canada
ABSTRACT
Introduction
The Economics and Patient Outcomes in Chinese Haemophilia (EPOCH) Study is a global collaboration initiating a patient register to observe quality of life (QoL), current standards, costs of care, and unmet needs for people with hemophilia in China. The study collects and houses all data on a server located in China, including patient reported outcomes (PRO), health economic data such as direct and indirect costs, and supporting clinical information to measure the impact of different treatment modalities and varying levels of treatment access. EPOCH is planned as a 3-year multi-center study; the pilot phase was initiated to assess the feasibility of the project on a large scale. This is a report of the PRO data collected by the first 209 enrolled in EPOCH during the pilot phase.
Methods
Data is collected through a network of core hemophilia treatment centers with participation by providers and patients. People with hemophilia complete an online questionnaire in which the PRO section includes both the Patient Reported Outcomes, Burdens, and Experiences (PROBE) study and ED-5D-5L. PROBE is a hemophilia-specific QoL scored between 0 and 1, where a score closer to 1 indicates better QoL. Clinical and treatment experience data is extracted by local primary investigators from electronic medical health records and the patient report form and clinician report form are matched by study ID number for robust analysis. Elements of the CHESS (Cost of Haemophilia in Europe/Across the US: a Socioeconomic Survey) Study are incorporated in the patient and clinician forms. EQ-5D health states were converted to index scores and were calculated using the UK and China value sets. Descriptive statistics for key demographic and QoL metrics are reported.
Results
Between August 2025 and June 2026, 209 participants enrolled and completed the Patient Report Form, comprised of 179 (85.6%) with hemophilia A and 30 (14.4%) with hemophilia B. Participant ages ranged from 10 to 70, with a median age of 18 years (IQR: 14-29). The majority of participants reported severe hemophilia with factor levels less than 1% (hemophilia A: n=150, 83.8%; hemophilia B: n=22, 73.3%). Participants were asked about their treatment regimens: regular prophylaxis was the most commonly reported, selected by 121 people with hemophilia A and 16 people with hemophilia B (67.6% and 53.3%, respectively), with 26 people with hemophilia A and 7 people with hemophilia B reporting “on demand” use (14.5% and 23.3%, respectively). Almost half of the participants reported experiencing chronic pain (hemophilia A: n=85, 47.5%, hemophilia B: n=14, 46.7%) and half of those participants indicated that the chronic pain impacted their activities of daily living. In this cohort, 66% reported they were full or part-time students, with 67.9% working full time, and the median number of days of school or work missed over the last 12 months was 1 (IQR: 0-8) and 2 (IQR:0-17) for people with hemophilia A and B, respectively. Fifty-one (28.5%) and 8 (26.7%) participants with hemophilia A and B, respectively, reported having a bleed in the past two weeks.
Median PROBE scores were 0.960 (IQR: 0.846-1.00) for people with hemophilia A and 0.954 (IQR: 0.866-0.998) for people with hemophilia B. Median EQ-5D using the China value set was 0.951 (IQR: 0.782-1.000) for people with hemophilia A and 0.893 (IQR: 0.831-1.000) for people with hemophilia B.
Conclusions
This first interim analysis demonstrates that the EPOCH data collection platform is viable. Enrollment continues steadily with a goal of 500 participants included in the pilot data set. The full data set will include health economics and clinical data which will be used to capture the full picture of the hemophilia experience for patients in China. Because the EPOCH platform utilizes elements from the PROBE and CHESS studies, previously collected data from other parts of the world can be used as a benchmark for comparison with the EPOCH data from China.
DISCLOSURES
Alfonso Iorio, MD, PhD: No relevant conflicts of interest to declare.